Entradas disclosed that its lead Duchenne muscular dystrophy candidate did not achieve the predefined primary efficacy endpoint, with functional assessments showing minimal difference from placebo at the specified time point.

Shares fell sharply on the announcement as investors adjusted expectations, while management said it will conduct a full data analysis to determine potential adjustments to the clinical program and regulatory strategy.